|Millions of dollars, except per share amounts||2014||2013||Change|
|Income from continuing operations||$1,185||$929||27.5%|
|Diluted earnings per share, from continuing operations||$5.99||$4.67||28.3%|
|Dividends per common share||$2.18||$1.98||10.1%|
Revenue by Region
(billions of dollars)
(1) Other is comprised of Latin America, Canada and Japan.
(billions of dollars)
*Amounts may not add due to rounding.
|BD Medical||BD Diagnostics||BD Biosciences|
|Physicians’ Office Practices|
|Consumers and Retail Pharmacies|
|Public Health Agencies|
|Academic and Government Institutions|
|Industrial and Food Microbiology Labs|
|Research and Clinical Laboratories|
|Alternate Site Healthcare|
BD Medical produces a broad array of medical devices that are used in a wide range of healthcare settings. BD Medical’s principal product lines include needles, syringes and intravenous catheters for medication delivery (including safety-engineered and auto-disable devices); prefilled IV flush syringes; syringes and pen needles for the injection of insulin and other drugs used in the treatment of diabetes; prefillable drug delivery systems provided to pharmaceutical companies and sold to end-users as drug/device combinations; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. The primary customers served by BD Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers.
BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections (“HAIs”) and cancers. BD Diagnostics’ principal products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; and plated media. BD Diagnostics serves hospitals, laboratories and clinics; reference laboratories; blood banks; healthcare workers; public health agencies; physicians’ office practices; and industrial and food microbiology laboratories.
BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. BD Biosciences’ principal product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media and supplements for biopharmaceutical manufacturing. The primary customers served by BD Biosciences are research and clinical laboratories; academic and government institutions; pharmaceutical and biotechnology companies; hospitals; and blood banks.
“As I look to the future, I see a Company that will have the ability to have a significant impact on the world’s healthcare problems on a scale that was not possible before, and to do it faster and with greater effectiveness.”
Vincent A. Forlenza
Chairman, Chief Executive Officer and President
In fiscal 2014, BD Biosciences launched BD FACSPresto™, an innovative near-patient CD4 counter system designed to bring CD4 testing closer to HIV/AIDS patients in resource-limited settings outside the U.S. It offers a full menu of CD4, %CD4 and hemoglobin results in a single test to stage and monitor HIV/AIDS patients (adults and children). It is small and portable, weighing only 7 kg (15 lbs), and operational using a rechargeable battery and across a wide range of temperature and humidity conditions.
The BD FACSPresto™ system measures the number of CD4 cells — a type of white blood cell that fights infection — to determine how strong the patients’ immune system is and the stage of their disease. This information is used to guide treatment and predict how the disease may progress. Because the BD FACSPresto™ system can bring CD4 testing closer to HIV/AIDS patients, it also helps increase the likelihood they will get access to treatment, which reduces the probability they will transmit new infections to others.
The BD FACSPresto™ system is unique in two important ways. First, it is easy to learn and use. Its features simplify operation without compromising accuracy and precision, including several built-in internal performance checks to ensure quality and consistency of testing as well as an intuitive language-independent graphical touchscreen interface and onboard operational videos. Second, clinical studies show it delivers finger-stick results that are as accurate, precise and reliable as venipuncture results.
The BD FACSPresto™ system is an extraordinary example of BD’s commitment to increasing access to healthcare and a strong asset in BD’s point-of-care (POC) strategy. The BD FACSPresto™ system is CE marked according to the EU IVD Directive 98/79/EC and has recently received the World Health Organization (WHO) Pre-Qualification.
In our Diagnostics Systems business, BD continues to expand the BD MAX™ System menu and its open system capabilities. For laboratories developing their own tests for the BD MAX™ System, we expanded our suite of Open System solutions with the introduction of the Total Nucleic Acid (TNA) suite of reagents. This innovation enables the development of assays capable of extracting and amplifying both DNA and RNA in a single reaction with an automated, simplified workflow.
In fiscal 2014, we also added new panels to our BD MAX™ Enteric suite. The BD MAX™ Enteric Parasite Panel can detect commonly isolated and highly pathogenic organisms in one panel, and the BD MAX™ Enteric Bacterial Panel can detect the most common causes of bacterial gastroenteritis. These assays provide clinicians with fast, accurate results that will enable more rapid diagnosis compared with conventional culture methods and will help improve standard of care and clinical efficiencies.
Over the past 10 years, the technology required to perform contrast-enhanced CT scans rapidly advanced, but the peripheral IV catheter used with such procedures had largely remained the same — until BD introduced its innovative BD Nexiva™ Diffusics™ power injection technology.
Modern diagnostic imaging often involves the use of a large IV catheter to inject contrast media into a patient’s bloodstream at a high flow rate to help radiologists identify the area of concern. The problem is that many patients cannot handle a large catheter due to their size (such as children) or because of poor vein health. The use of smaller catheters with these patients may result in excessive catheter motion that may injure the vein or suboptimal imaging caused by a reduced contrast flow rate.
We designed the BD Nexiva™ Diffusics™ Closed IV Catheter System to address three specific challenges — insertion difficulties, suboptimal contrast delivery and extravasation. Its all-in-one design is built for a 325 psi power injection setting, and its unique diffuser hole design lessens the impact to the vein during power injection compared to non-diffused catheters. Using laser technology, BD modified the tip of the IV catheter to evenly distribute the contrast flow into the vein, making it possible to perform most CT scans using a smaller gauge size catheter at the desired flow rate. This can help improve the experience for both the patient and clinician.